Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Women’s Health Initiative Advisory Committee Meeting Postponed

Executive Summary

The Nov. 12-13 meeting of the Women's Health Initiative Subcommittee of FDA's Reproductive Health Drugs Advisory Committee has been postponed
Advertisement

Related Content

Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
FDA Reproductive Health Cmte. Line-Up Set; First Priority Will Be WHI Results
FDA Reproductive Health Cmte. Line-Up Set; First Priority Will Be WHI Results
FDA Hormone Therapy Risk Management Options Include Narrower Indication
FDA Hormone Therapy Risk Management Options Include Narrower Indication
Prempro WHI Implications For Future HRT Trials To Be Discussed By Subcmte.
Prempro WHI Implications For Future HRT Trials To Be Discussed By Subcmte.
FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford
Advertisement
UsernamePublicRestriction

Register

PS040687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel